Veradermics, Incorporated (NYSE: MANE) has reported twelve-month topline results from Study 302 showing sustained improvements in hair growth among men receiving its investigational extended-release oral minoxidil formulation, VDPHL01. The November 9, 2026, findings showed mean increases from baseline of 43.9 non-vellus hairs per square centimetre with twice-daily dosing and 29.7 hairs per square centimetre with once-daily dosing, extending the clinical evidence supporting the company’s registration-directed development programme for male pattern hair loss.
The development provides an important update beyond the six-month placebo-controlled findings reported earlier in 2026. Those earlier results established statistically significant improvements in hair count and patient-reported coverage compared with placebo, while the latest extension findings offer additional information about the persistence of treatment effects and longer-term tolerability. However, Study 302’s second six-month period did not retain an untreated placebo comparison, meaning the twelve-month findings should be interpreted as longitudinal treatment observations rather than a new placebo-controlled efficacy result.
Veradermics announced on November 12 that management would present at the Jefferies Global Healthcare Conference in London on November 19, 2026. The presentation announcement itself contained no new clinical results, but it follows several substantial developments in the VDPHL01 programme, including positive six-month Phase 3 data from Study 304 and the newly disclosed twelve-month Study 302 results. Together, these developments move investor attention towards the completeness of the regulatory evidence package and the programme’s remaining safety and commercial uncertainties.
What do the twelve-month Study 302 results reveal about sustained VDPHL01 hair growth?
Study 302 enrolled 519 men with mild-to-moderate pattern hair loss and initially randomised participants to once-daily VDPHL01 8.5 mg, twice-daily VDPHL01 8.5 mg or placebo. Its first six months provided the controlled efficacy period, after which placebo participants crossed over to active treatment during a six-month extension. The longer observation period was intended to generate additional information about treatment exposure, durability and tolerability.
Among participants who continued receiving VDPHL01, the twice-daily group recorded a mean increase of 43.9 non-vellus hairs per square centimetre from baseline at Month 12. The corresponding figure for once-daily treatment was 29.7 hairs per square centimetre. These measurements represent hair density changes within the predefined target area rather than the absolute number of additional hairs across the entire scalp.
The pattern of change across treatment duration is relevant. Veradermics’ disclosed data show that the twice-daily group recorded a mean increase of 33.0 hairs per square centimetre at six months, rising to 43.9 at twelve months, while the once-daily group’s corresponding result moved from 30.3 to 29.7. The findings therefore indicate a further numerical increase in the twice-daily group and broadly maintained hair density in the once-daily group.
Those observations strengthen the case that the measured benefits were not confined to the initial treatment period. Nevertheless, the extension results do not establish that twice-daily administration is definitively superior as a long-term regimen, particularly without a contemporaneous placebo comparison during the second half of the study. Patient retention, available data and differences in exposure also need to be considered when interpreting longitudinal results.
The company additionally reported hair growth among participants who switched from placebo to VDPHL01 after six months. At Month 12, these participants showed mean increases from their original baseline of 32.1 hairs per square centimetre with twice-daily administration and 24.5 with once-daily administration. These findings provide supportive observations from patients who began active treatment later, although they do not replace the controlled efficacy analyses.
How do patient-reported outcomes support the objective hair count findings?
Hair density measurements provide a quantitative assessment of treatment activity, but they do not necessarily capture how patients perceive the appearance of their hair. In pattern hair loss, this distinction matters because modest changes in a predefined scalp area may not correspond directly to visible improvements that patients consider worthwhile. Veradermics therefore uses both objective hair counts and patient-reported changes in coverage in its clinical development programme.
At twelve months, 89.1% of participants in the continued twice-daily treatment group and 79.8% in the continued once-daily group reported some visible improvement in hair coverage using the Androgenetic Alopecia Impact Rating Scale. Applying the stricter categories of improved or much improved, the corresponding proportions were 68.0% and 48.4%. These measurements provide different levels of response, so the larger percentages should not be presented as though every participant experienced substantial improvement.
Investigator assessments also supported the general direction of the findings. Veradermics reported improved hair coverage according to investigators in 92.2% of participants receiving twice-daily treatment and 74.4% receiving once-daily treatment. Agreement between objective hair measurements, patient reports and investigator observations strengthens the interpretation that continued treatment produced visible changes for a substantial proportion of participants.
However, the extension’s lack of an untreated control group limits the conclusions that can be drawn about the magnitude of treatment-attributable benefit at twelve months. Patient-reported assessments may also be influenced by expectations, prior treatment experience and awareness of receiving active therapy. The six-month randomised comparisons therefore remain more informative for establishing efficacy, while the extension provides useful supplementary evidence about persistence.
The distinction will matter during regulatory assessment. A medicine intended for chronic use must offer benefits that are clinically meaningful, reasonably durable and appropriately balanced against treatment burden and adverse effects. Consistency across endpoints is encouraging, but the final assessment will depend on the full trial datasets and the proposed indication.
Does the extended safety evidence resolve concerns about systemic oral minoxidil?
The safety profile is central to VDPHL01’s regulatory and commercial prospects because minoxidil is a systemically active vasodilator. Although oral minoxidil is used in dermatology, existing oral formulations were originally developed for severe hypertension and have recognised cardiovascular risks. The development of an extended-release formulation therefore requires evidence that its pharmacokinetic characteristics support an acceptable benefit-risk profile for the intended hair loss population.
Veradermics reported no treatment-related serious adverse events, no adverse events of special interest of cardiac origin and no newly identified safety signals during Study 302’s disclosed twelve-month observation. The company also reported no treatment-emergent adverse events leading to discontinuation between Months 6 and 12 among participants continuing VDPHL01. These findings provide additional reassurance within the studied population and exposure period.
They do not establish that VDPHL01 is free from clinically important cardiovascular risks. The interpretation of uncommon adverse events depends on the number of patients exposed, their underlying health characteristics, the duration of treatment and the intensity of safety monitoring. Even a development programme involving more than 1,000 male participants may be insufficient to exclude rare complications that could become apparent during substantially broader use.
The earlier six-month Study 304 findings included peripheral oedema and hypertrichosis among reported adverse events, illustrating why tolerability requires consideration alongside hair growth. A larger numerical improvement in hair count may not always correspond to the preferred treatment regimen if adverse effects, dosing frequency or other practical considerations differ. Regulatory reviewers will therefore need to evaluate dose-specific benefits and risks rather than focusing exclusively on the highest efficacy measurement.
Veradermics has described its proprietary extended-release technology as a way to modify minoxidil exposure and potentially reduce concentration-related risks. Whether those pharmacokinetic characteristics translate into a sufficiently differentiated clinical safety profile will depend on the complete evidence package. Direct superiority over conventional oral minoxidil should not be inferred from comparisons between separate development programmes.
Why does Study 306 remain a separate clinical milestone for female pattern hair loss?
Veradermics is also developing VDPHL01 for women with pattern hair loss, a population with distinct clinical and treatment considerations. Its Phase 2/3 Study 306 enrolled 556 women with mild-to-moderate pattern hair loss and evaluates lower 4.5 mg once-daily and twice-daily regimens. The company expects to report topline results during the first half of 2027.
Earlier open-label Phase 2 findings from Study 207 supported further evaluation in women, but the absence of a placebo-controlled comparison means those data cannot independently establish confirmatory efficacy. Study 306 is designed to provide controlled evidence using hair count and patient-reported coverage endpoints. Its results will therefore be important in determining whether the VDPHL01 programme can support development across both male and female populations.
The male registration-directed studies cannot automatically establish effectiveness or an acceptable benefit-risk profile in women. Differences in dose, physiological characteristics, treatment expectations and underlying clinical considerations require the female programme to be evaluated on its own evidence. Approval for one population would not constitute approval for the other.
The timing also affects Veradermics’ potential commercial strategy. Successful development in men would establish one possible market opportunity, while positive female data could support an additional indication subject to the necessary regulatory review. However, the company must avoid assuming that favourable outcomes in one population predict success in another.
Can Veradermics’ financial position support the transition towards commercial readiness?
Veradermics reported approximately $798.4 million in cash, cash equivalents and marketable securities at September 30, 2026. Management expects these resources to support planned operations into 2030, including continued clinical development and preparations for a potential VDPHL01 launch. That funding position provides considerable flexibility compared with biotechnology companies whose next clinical readout is also an immediate financing event.
Commercial readiness nevertheless introduces requirements beyond completing clinical studies. Veradermics will need to establish appropriate manufacturing arrangements, quality systems, distribution capabilities, medical affairs support and physician engagement if VDPHL01 receives regulatory approval. Dermatologists will also need to understand the eventual product label, dose-specific safety findings and appropriate patient selection.
The company’s potential competition includes established topical treatments, prescription oral options and off-label oral minoxidil use. A proprietary formulation may offer advantages in dosing or exposure characteristics, but commercial differentiation must be demonstrated through clinically relevant evidence and a viable pricing proposition. Insurance coverage may also be limited for treatments considered primarily aesthetic, making patient out-of-pocket costs an important adoption consideration.
The financial position reduces the urgency of near-term capital raising, but it does not eliminate commercial uncertainty. A substantial cash balance cannot guarantee regulatory approval, favourable reimbursement or rapid adoption. The investment case increasingly depends on whether Veradermics can convert its clinical evidence into a product that clinicians and patients consider meaningfully differentiated.
What should investors and dermatologists expect after the Jefferies presentation?
The November 19 Jefferies Global Healthcare Conference offers Veradermics an opportunity to explain how the twelve-month Study 302 findings fit into its broader regulatory strategy. The scheduled management presentation is not a regulatory milestone and should not be interpreted as an indication that the United States Food and Drug Administration has accepted or approved an application. Its value will depend on any substantive clarification of development priorities, timelines and the complete evidence package.
The next major clinical milestone remains the anticipated Study 306 readout in women during the first half of 2027. For the male programme, the central questions concern how the full twelve-month safety findings, dose selection and placebo-controlled efficacy results will support the proposed regulatory indication. More detailed safety and clinical analyses may also help establish the practical differences between once-daily and twice-daily treatment.
The twelve-month findings give Veradermics a stronger durability narrative than was available after the six-month studies alone. Yet the transition from statistically significant hair growth to an approved prescription product requires a complete benefit-risk assessment, and the extension results cannot substitute for that regulatory process. The company’s progress is increasingly measurable, but the final clinical and commercial value of VDPHL01 will depend on the breadth of evidence accepted by regulators and the treatment proposition available to dermatologists after any approval.
